Sarah Pratap - Concepedia

Author

Sarah Pratap

University of Oxford ORCID

Also Known As

S Pratap, S Pratap Rai, S. E. Pratap, S. Pratap, S.E. Pratap, Sarah E Pratap, Sarah Pratap, Surya Madadi Pratap

Publications

3.6K

Citations

H-Index

Concepts

All Affiliations

University of Oxford Churchill Hospital John Radcliffe Hospital Nuffield Orthopaedic Centre Leiden University Medical Center

About

Sarah Pratap is an author at University of Oxford specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	901
2	Pathology	4	4	848
3	Immunology	3	3	812
4	Cell Biology	1	1	585
5	Orthopaedics	1	1	36

Sarah Pratap

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level Giovanna Roncador, Philip J. Brown, Lorena Maestre, European Journal of Immunology T-regulatory CellImmunologyImmune RegulationPathologyRegulatory T Cells	2005	585
Identification of randomized controlled trials in systematic reviews: accuracy and reliability of screening records Phil Edwards, Carolyn DiGuiseppi, Sarah Pratap, Statistics in Medicine	2002	314
Trajectories of drinking from 18 to 26 years: identification and prediction Sally Casswell, Megan Pledger, Sarah Pratap Addiction	2002	225
Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Khoon Lin Ling, Sarah Pratap, Gaynor J. Bates, PubMed Cancer ImmunosurveillanceMedicineT-regulatory CellImmunologyTumor Immunity	2007	173
Retrospective audit of 957 consecutive 18F-FDG PET–CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma Ruth E. Macpherson, Sarah Pratap, Helen E.J. Tyrrell, Clinical Sarcoma Research	2018	109
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hans Gelderblom, Vivek A. Bhadri, Silvia Stacchiotti, The Lancet Surgical OncologyMedicineImmunologyPathologyImmune Checkpoint Inhibitor	2024	54
A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan Rachel Midgley, Keith T. Flaherty, James Stevenson, Annals of Oncology Pharmaceutical ScienceMedicinePharmacologyPharmacokinetic StudyPharmacotherapy	2007	53
<scp>NY‐ESO</scp> ‐1 specific antibody and cellular responses in melanoma patients primed with <scp>NY‐ESO</scp> ‐1 protein in <scp>ISCOMATRIX</scp> and boosted with recombinant <scp>NY‐ESO</scp> ‐1 fowlpox virus Ji‐Li Chen, Amina Dawoodji, Andrea Tarlton, International Journal of Cancer	2014	48
Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR Tamara Aleksic, Lisa Browning, Martha Woodward, Frontiers in Oncology Surgical OncologyChordoma BiologyPathologyCombined InhibitionSpine Deformity	2016	36
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma Sarah Pratap, ISD Roberts, Jane Collier, BMC Cancer	2012	29

Page 1